E
Eduardo Vilar-Gomez
Researcher at Indiana University
Publications - 62
Citations - 3547
Eduardo Vilar-Gomez is an academic researcher from Indiana University. The author has contributed to research in topics: Cirrhosis & Fatty liver. The author has an hindex of 16, co-authored 49 publications receiving 2183 citations. Previous affiliations of Eduardo Vilar-Gomez include Indiana University – Purdue University Indianapolis & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
Eduardo Vilar-Gomez,Yadina Martinez-Perez,Luis Calzadilla-Bertot,Ana Torres-Gonzalez,Bienvenido Gra-Oramas,Licet Gonzalez-Fabian,Scott L. Friedman,Moisés Diago,Manuel Romero-Gómez +8 more
TL;DR: A greater extent of weight loss, induced by lifestyle changes, is associated with the level of improvement in histologic features of NASH.
Journal ArticleDOI
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez,Eduardo Vilar-Gomez,Luis Calzadilla-Bertot,Vincent Wai-Sun Wong,Marlen Castellanos,Rocio Aller-de la Fuente,Mayada Metwally,Mohammed Eslam,Licet Gonzalez-Fabian,María Alvarez-Quiñones Sanz,Antonio Felix Conde-Martin,Bastiaan De Boer,Duncan McLeod,Anthony W.H. Chan,Naga Chalasani,Jacob George,Leon A. Adams,Manuel Romero-Gómez +17 more
TL;DR: Patients with NAFLD cirrhosis have predominantly liver-related events, whereas those with bridging fibrosis have predominantly nonhepatic cancers and vascular events, and moderate alcohol consumption was associated with these outcomes only in patients with Cirrhosis.
Journal ArticleDOI
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
TL;DR: Currently available clinical prediction rules and blood-based biomarkers for identifying NASH and advanced fibrosis in patients with NAFLD are described, discussing their advantages and disadvantages, as well as their potential clinical utility for predicting dynamic changes over time and identifying patients at increased risk of adverse outcomes.
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
Eduardo Vilar-Gomez,Eduardo Vilar-Gomez,Luis Calzadilla-Bertot,Vincent Wai-Sun Wong,Marlen Castellanos,Rocio Aller-de la Fuente,Mayada Metwally,Mohammed Eslam,Licet Gonzalez-Fabian,María Alvarez-Quiñones Sanz,Antonio Felix Conde-Martin,Bastiaan De Boer,Duncan McLeod,Anthony W.H. Chan,Naga Chalasani,Jacob George,Leon A. Adams,Manuel Romero-Gómez +17 more
TL;DR: In this paper, the authors describe long-term outcomes and evaluate the effects of clinical and histologic parameters on disease progression in patients with advanced nonalcoholic fatty liver disease (NAFLD) with bridging fibrosis.
Journal ArticleDOI
Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis.
Eduardo Vilar-Gomez,Raj Vuppalanchi,Samer Gawrieh,Marwan Ghabril,Romil Saxena,Oscar W. Cummings,Naga Chalasani +6 more
TL;DR: Vitamin E use was associated with improved clinical outcomes in patients with NASH and bridging fibrosis or cirrhosis, and these benefits were evident in both those with diabetes and those without diabetes.